Fulgent Genetics Stock Investor Sentiment

FLGT Stock  USD 18.95  0.17  0.91%   
Slightly above 51% of Fulgent Genetics' investor base is interested to short. The analysis of overall sentiment of trading Fulgent Genetics stock suggests that many investors are impartial at this time. Fulgent Genetics' investing sentiment can be driven by a variety of factors including economic data, Fulgent Genetics' earnings reports, geopolitical events, and overall market trends.
  

Fulgent Genetics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Fulgent Genetics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Fulgent Genetics Maximum Pain Price Across January 17th 2025 Option Contracts

Fulgent Genetics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Fulgent Genetics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Fulgent Genetics' options.
over three months ago at seekingalpha.com         
Disposition of 1337 shares by Ming Hsieh of Fulgent Genetics at 23.57 subject to Rule 16b-3
seekingalpha News
over three months ago at www.macroaxis.com         
Disposition of 111 shares by Gao Hanlin of Fulgent Genetics at 23.95 subject to Rule 16b-3
Macroaxis News
over three months ago at www.macroaxis.com         
Disposition of 1154 shares by Gao Hanlin of Fulgent Genetics at 23.66 subject to Rule 16b-3
Macroaxis News
over three months ago at news.google.com         
SG Americas Securities LLC Cuts Stake in Fulgent Genetics, Inc. - Defense World
Google News at Macroaxis
over three months ago at finance.yahoo.com         
Fulgent Genetics Soars 6.6 percent Is Further Upside Left in the Stock?
Yahoo News
over three months ago at simplywall.st         
Some Shareholders Feeling Restless Over Fulgent Genetics, Inc.s PS Ratio
Simply Wall St News at Macroaxis
over three months ago at news.google.com         
Fulgent Genetics, Inc. Position Increased by Empowered Funds LLC - Defense World
Google News at Macroaxis
over six months ago at businesswire.com         
Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024
businesswire News
over six months ago at www.macroaxis.com         
Disposition of 6719 shares by Jian Xie of Fulgent Genetics at 24.65 subject to Rule 16b-3
Macroaxis News
over six months ago at news.google.com         
Short Interest in Fulgent Genetics, Inc. Increases By 8.7 percent - MarketBeat
Google News at Macroaxis
over six months ago at finance.yahoo.com         
With 50 percent ownership, Fulgent Genetics, Inc. boasts of strong institutional backing
Yahoo News
over six months ago at www.macroaxis.com         
Disposition of 5504 shares by Gao Hanlin of Fulgent Genetics at 24.025 subject to Rule 16b-3
Macroaxis News
over six months ago at news.google.com         
Long Term Investment Analysis - Stock Traders Daily
Google News at Macroaxis
over six months ago at news.google.com         
Park West Asset Management LLC Buys 79,649 Shares of Fulgent Genetics, Inc. - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
Fulgent Genetics Sets New 52-Week Low at 19.85 - Defense World
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Fulgent Genetics that are available to investors today. That information is available publicly through Fulgent media outlets and privately through word of mouth or via Fulgent internal channels. However, regardless of the origin, that massive amount of Fulgent data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Fulgent Genetics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Fulgent Genetics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Fulgent Genetics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Fulgent Genetics alpha.

Fulgent Genetics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Gao Hanlin of 27 shares of Fulgent Genetics subject to Rule 16b-3
10/14/2024
2
Disposition of 4345 shares by Jian Xie of Fulgent Genetics at 19.42 subject to Rule 16b-3
10/25/2024
3
Disposition of tradable shares by Gao Hanlin of Fulgent Genetics at 20.27 subject to Rule 16b-3
10/30/2024
4
Fulgent to Participate in Upcoming Conferences
11/05/2024
5
Fulgent Genetics Downgraded to Sell Rating by StockNews.com
11/12/2024
6
Fulgent Genetics Hits New 52-Week Low Heres What Happened
11/19/2024
7
Fulgent Genetics, Inc. Among the Best Genomics Stocks to Buy Right Now
11/20/2024
8
Gene Panel Market to Surpass USD 11.75 Billion by 2031 SkyQuest Technology
11/22/2024
9
Disposition of 689 shares by Jian Xie of Fulgent Genetics at 18.2593 subject to Rule 16b-3
11/25/2024
10
Fulgent Genetics CEO Ming Hsieh sells 40,663 in stock
11/27/2024
11
Disposition of 1553 shares by Paul Kim of Fulgent Genetics at 18.3 subject to Rule 16b-3
11/29/2024
12
Disposition of 1373 shares by Gao Hanlin of Fulgent Genetics at 19.4999 subject to Rule 16b-3
12/03/2024
13
Fulgent Genetics chief scientific officer sells 26,773 in stock
12/04/2024
14
Wall Street Analysts Predict a 31.06 percent Upside in Fulgent Genetics Heres What You Should Know
12/09/2024
15
Acquisition by Jian Xie of 27 shares of Fulgent Genetics subject to Rule 16b-3
12/10/2024
16
Fulgent Genetics, Inc. Shares Purchased by BNP Paribas Financial Markets - MarketBeat
12/11/2024

Additional Tools for Fulgent Stock Analysis

When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.